Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015   California Cryobank Stem ... acquisition of LifeLine Cryogenics, an east coast cord blood ... New York tristate area. LifeLine clients will ... prepaid contracts will be honored. Since 1991, ... offering storage of sperm, eggs, embryos, and cord blood ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
(Date:8/3/2015)... ... 2015 , ... The synthetic rubber industry is recognized as ... ethylbenzene, a precursor to styrene, used to make styrene-butadiene resins, styrene butadiene latex, ... of tyres and other components. Thus, growth in the automotive industry is the ...
(Date:8/3/2015)... Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ... treat life-threatening diseases, today announced that it will host ... webcast on Thursday, August 13, 2015 at 4:30 p.m. ... follow the release of fiscal 2016 first quarter results.  ... approximately two hours after the call at the Investor ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2ArroGen Previews New Fingerprint Molecular Identification Technology 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2
... 2 Vermillion, Inc. (OTC Bulletin Board: VRML) today ... reorganization relief under Chapter 11 of the United States ... the District of Delaware ("Bankruptcy Court") in Wilmington, Delaware. ... as it focuses on obtaining regulatory clearance respecting the ...
... 2 Shire plc (LSE: SHP,NASDAQ: SHPGY ... the U.S. District,Court for the Southern District of New ... of Shire,s patents: U.S. Patent No.,5,968,976 (",976 Patent"); and ... The lawsuit was filed in response to ...
... test for detection of methicillin-resistant Staphylococcus aureus for better ... that its new LightCycler(R) test for the detection of ... with the CE Mark, allowing it to be sold ... MRSA Advanced Test is a qualitative in vitro ...
Cached Biology Technology:Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code 2Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code 3Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code 4Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code 5Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents 2Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 2Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 3Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 4
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... Researchers at Southern Methodist University (SMU) and The University ... of chemical compounds that slow the degeneration of neurons, ... amyotrophic lateral sclerosis (ALS). Their findings ... Experimental Biology and Medicine . SMU Chemistry Professor Edward ...
... scientists say they are forging ahead with plans ... creation of critically needed nanotechnology standards, including the ... of nanotech products while minimizing potential risks. ... with those of biological and medical researchers, the ...
... Energy and Environmental Policy Research have produced a report ... are under consideration in the United States as a ... of the three-part study found that, based on an ... U.S. programs for other emissions, such a program can ...
Cached Biology News:Protecting neurons could halt Alzheimer's, Parkinson's diseases 2NIST, NCI bring web 2.0 tools to nanotechnology standards effort 2MIT analysis shows how cap-and-trade plans can cut greenhouse emissions 2
Form: Concentrated Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Form: Ready to use Applications: Western Blot, ELISA...
... Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs of Abuse, and Industrial Testing applications. ... ... ... ...
Biology Products: